Selected Podcast

AI - The Next Era of Diagnostic Intelligence

Join the conversation as Dr. Yuri Feskow, MD (Chief Medical Officer, Quest Diagnostics) and Nicole Antonson (Vice President, Digital Solutions & Interoperability, Quest Diagnostics) discuss the “AI Companion” approach that turns complex lab results into clear guidance patients can act on. AI is moving from novelty to baseline capability in diagnostics, from digital pathology to patient-facing tools that translate lab data into actionable next steps. Learn about AI in healthcare, diagnostic intelligence, digital pathology, clinical decision support, and why health systems should prioritize clinically driven, secure implementations.

Visit Quest Diagnostics to learn more


AI - The Next Era of Diagnostic Intelligence
Featured Speakers:
Yuri Fesko, MD | Nicole Antonson

Yuri Fesko, M.D., is Senior Vice President and Chief Medical Officer (CMO) of Quest Diagnostics. He assumed the role of CMO in December 2023.As CMO, Dr. Fesko is responsible for overseeing medical affairs, including clinical development and health plan policy support for new services and care delivery models. He also leads scientific communications for the company’s medical team of approximately 600 M.D.s and Ph.D.s. Since joining Quest in 2016, Dr. Fesko has held several roles of increasing responsibility, most recently as Vice President of Medical Affairs and Senior Medical Director for the company’s oncology services. Board certified in oncology, hematology and internal medicine, Dr. Fesko led clinical development of several innovations for Quest, including the company’s 500 gene somatic tumor next-generation sequencing panel as well as the company’s decentralized clinical trials model. He also pioneered the company’s precision pathways model of care, which helps oncologists and pathologists at health systems speed guideline-based biomarker testing for advanced cancers. In addition, he led clinical research on the minimal residual disease (MRD) test technology developed by Haystack Oncology, informing Quest’s decision to acquire the company in 2023 to establish a position in cancer recurrence testing. Prior to joining Quest, Dr. Fesko was medical director of oncology for Duke Cancer Center in Raleigh, N.C., where he focused on genitourinary oncology and multiple myeloma, and was chief of oncology for Wake County, N.C. Dr. Fesko completed his fellowship in hematology and oncology and earned his medical and bachelor's degrees from Case Western Reserve University in Cleveland. He is author of multiple peer reviewed publications. 


Nicole Antonson is the VP of Digital Solutions and Interoperability at Quest Diagnostics. Before joining Quest Diagnostics, she led digital product teams at Elevance/Carelon as VP, Advanced Analytics Business Solutions Leader and at McKesson/Change Healthcare, in various roles, including VP of Patient Access Solutions and VP of Identity and CommonWell Services. With a career in healthcare IT spanning over two decades, Nicole is a proven leader dedicated to developing innovative solutions which ease patient, provider, and payer workflows. She specializes in making healthcare information accessible and actionable, with deep expertise in data interoperability, analytics, and how to deliver provider and patient-centric solutions at scale. Nicole holds a master’s in business administration from the Katz School of Business at the University of Pittsburgh and bachelors’ degrees in nursing and biology from University of Pittsburgh and University of Michigan respectively. This unique combination of degrees gives her a comprehensive understanding of both the clinical and business sides of healthcare.